MDACC Study No:2011-0919 ( NCT No: NCT01585194)
Title:Phase I/II Study of Ipilimumab for Uveal Melanoma
Principal Investigator:Sapna P. Patel
Treatment Agent:Ipilimumab
Study Status:Open
Study Description:The goal of this clinical research study is to learn the highest tolerable dose
of ipilimumab that can be given to patients with uveal melanoma. Researchers
also want to learn if ipilimumab can help to control the disease.

Ipilimumab is designed to increase the immune system's ability to fight cancer.

Hide details for General InformationGeneral Information

Disease Group:Melanoma
Phase of Study:Phase I/Phase II
Treatment Agents:Ipilimumab
Treatment Location:Only at MDACC
Estimated Length of Stay in Houston:
Supported By:Bristol Myers Squibb
University of Texas, MD Anderson Cancer Center
Return Visit:
Home Care:

Hide details for Study Contact InformationStudy Contact Information

Physician Name:Sapna P. Patel
Dept:Melanoma Medical Oncology
For Clinical Trial Enrollment:713-792-2921
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)

Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults